Research programme: hypercholesterolaemia therapies - Incyte

Drug Profile

Research programme: hypercholesterolaemia therapies - Incyte

Alternative Names: MX 6046; MX 7291

Latest Information Update: 19 Sep 2006

Price : $50

At a glance

  • Originator Incyte Corporation
  • Class
  • Mechanism of Action Cholesterol absorption inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hypercholesterolaemia

Most Recent Events

  • 19 Sep 2006 Discontinued - Preclinical for Hypercholesterolaemia in USA (unspecified route)
  • 30 Apr 2003 Incyte Genomics is now called Incyte Corporation
  • 03 Mar 2003 Maxia Pharmaceuticals has been acquired by Incyte Genomics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top